Sanner Ventures and Amiko Digital Health have announced a deal in which Sanner will make a strategic investment in further development of Amiko’s Respiro dry powder inhaler monitoring platform.
Amiko also announced that the Respiro platform has received the CE mark for use with the Spiromax, Nexthaler, and Ellipta inhalers. According to Amiko, the company has received ISO 13485:2016 certification in addition to the CE mark and therefore expects that it will be able to begin marketing Respiro in Europe sometime in 2018.
Sanner GmbH Managing Director Dirk Mähr said, “Sanner has profound experience in moisture protection solutions and custom-made primary plastic packaging, as well as in design for manufacturing and industrialization of drug delivery systems. Together with Amiko’s digital Respiro Platform and unique sensor technology, we will transform our synergies into smart solutions for true medication adherence in respiratory care.”
Amiko CEO and Co-Founder Duilio Macchi commented, “Our digital health tools assist healthcare professionals and empower patients to achieve better respiratory treatment results. Together with Sanner we will advance our mission to upgrade respiratory care, improve health outcomes and reduce the costs of care for pulmonary diseases via AI-powered mobile health solutions.”
Amiko Director of Regulatory Affairs Federica Iovine said, “Receiving the CE Mark is a significant milestone toward the global commercialization of our connected inhaler technology. By successfully completing this process, Amiko has demonstrated that Respiro complies with applicable EU’s health and safety legislative requirements and it can now offer the technology for clinical and commercial use to healthcare providers and research institutions in the EU.”
Read the Sanner and Amiko press release on the strategic investment.
Read the Amiko press release on the CE mark.
